Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $46.94, for a total transaction of $821,450.00. Following the completion of the transaction, the chief executive officer now directly owns 85,942 shares in the company, valued at $4,034,117.48. This represents a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.39, for a total transaction of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The stock was sold at an average price of $38.24, for a total transaction of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $44.05 on Monday. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $2.79 billion, a P/E ratio of -16.88 and a beta of 1.08. The firm has a 50-day moving average price of $45.00 and a two-hundred day moving average price of $40.36. Vera Therapeutics, Inc. has a twelve month low of $14.08 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on VERA. Scotiabank assumed coverage on Vera Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $60.00 price target for the company. Guggenheim boosted their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Wedbush increased their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Vera Therapeutics has a consensus rating of “Buy” and an average price target of $59.22.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after purchasing an additional 350 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Vera Therapeutics during the 2nd quarter worth about $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vera Therapeutics during the second quarter worth about $163,000. Cetera Advisors LLC acquired a new position in shares of Vera Therapeutics in the first quarter valued at approximately $235,000. Finally, Quarry LP purchased a new position in shares of Vera Therapeutics during the second quarter valued at approximately $235,000. 99.21% of the stock is owned by institutional investors and hedge funds.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.